TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Expected volatility, share options granted

80.00%

90.00%

Number of shares issued | shares

63,280

1,744,913

^[1]

1,744,913

^[1]

390,952

^[1]

11,678

15,891

Price per share | (per share)

$ 6.51

£ 5.41

$ 7.565

£ 6.362

£ 215.00

Two Thousand Twenty One Share Option Scheme [Member]

Weighted average share price | $ / shares

$ 53.42

Expense from share-based payment transactions

£ 1,123,250

Enterprise Management Incentive Share Option Scheme [Member]

Weighted average share price | £ / shares

Expense from share-based payment transactions

Expected volatility, share options granted

75.00%

Two Thousand Twenty One Share Option Scheme [Member]

Expected volatility, share options granted

80.00%

[1]

On November 18, 2022 the Company undertook a reverse share split such that fifty issued ordinary shares were exchanged for one new. As a result of the reverse share split, all references in these financial statements and accompanying notes to units of ordinary shares or per share amounts are reflective of the reverse share split for all periods presented.

- References

No definition available.

Name:	TCBP_IfrsStatementLineItems
Namespace Prefix:	TCBP_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2022-03-24
-Paragraph 47
-Subparagraph a
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard
-URIDate 2022-03-24

Name:	ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2022-03-24
-Paragraph 51
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard
-URIDate 2022-03-24

Name:	ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The number of shares issued by the entity.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 106
-Subparagraph d
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2022-03-24

Name:	ifrs-full_NumberOfSharesIssued
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

The nominal value per share.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 79
-Subparagraph a
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard
-URIDate 2022-03-24

Name:	ifrs-full_ParValuePerShare
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

The weighted average share price. [Refer: Weighted average [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2022-03-24
-Paragraph 45
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard
-URIDate 2022-03-24